On April 19, 2024, Biodexa Pharmaceuticals PLC, a clinical-stage biopharmaceutical company listed on NASDAQ under the ticker BDRX, announced its preliminary results for the fiscal year ending December 31, 2023. The company, which focuses on developing treatments for primary and metastatic cancers of the brain, including Type 1 diabetes and rare/orphan brain cancers, reported on its progress and financial performance. Biodexa's lead development programs include tolimidone and MTX110, with the former being a novel agent for Type 1 diabetes treatment and the latter being studied for aggressive brain cancer indications. The company's proprietary drug delivery technologies aim to improve the bio-delivery and bio-distribution of medicines. Biodexa's headquarters and R&D facility are located in Cardiff, UK. The announcement also included...Show More

On April 19, 2024, Biodexa Pharmaceuticals PLC, a clinical-stage biopharmaceutical company listed on NASDAQ under the ticker BDRX, announced its preliminary results for the fiscal year ending December 31, 2023. The company, which focuses on developing treatments for primary and metastatic cancers of the brain, including Type 1 diabetes and rare/orphan brain cancers, reported on its progress and financial performance. Biodexa's lead development programs include tolimidone and MTX110, with the former being a novel agent for Type 1 diabetes treatment and the latter being studied for aggressive brain cancer indications. The company's proprietary drug delivery technologies aim to improve the bio-delivery and bio-distribution of medicines. Biodexa's headquarters and R&D facility are located in Cardiff, UK. The announcement also included forward-looking statements cautioning that actual results could differ materially from projected outcomes due to numerous factors such as regulatory risks, capital requirements, and competition. The company's financial review highlighted a net loss for the year and significant cash outflows from operating activities, with an accumulated deficit as of December 31, 2023. Biodexa's future viability depends on its ability to raise capital to finance its development plans. The company's financial statements have been prepared on a going concern basis, with the acknowledgment of a material uncertainty that may cast significant doubt on the company's ability to continue as a going concern without additional financing.